ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,062.00
-0.10%
다우존스 지수
40,003.59
0.34%
Bitcoin
66,278.09
-0.99%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Sensei Biotherapeutics Inc (SNSE)

  7. Sensei Biotherapeutics Inc (SNSE) 뉴스

SNSE

Sensei Biotherapeutics (SNSE)

Sensei Biotherapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:SNSE
일자시간출처헤드라인심볼기업
2024/05/1005:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNSESensei Biotherapeutics Inc
2024/05/0920:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2024/03/0606:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2024/02/2821:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2024/02/1708:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2024/02/1708:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2024/02/1708:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2024/02/0906:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2024/01/0422:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0806:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0721:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0721:30GlobeNewswire Inc.Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0620:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0405:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0405:05GlobeNewswire Inc.Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0305:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0305:50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0120:30GlobeNewswire Inc.Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business OfficerNASDAQ:SNSESensei Biotherapeutics Inc
2023/10/2522:05GlobeNewswire Inc.Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
2023/10/2320:30GlobeNewswire Inc.Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023NASDAQ:SNSESensei Biotherapeutics Inc
2023/10/2106:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/2720:30GlobeNewswire Inc.Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®NASDAQ:SNSESensei Biotherapeutics Inc
2023/09/2120:30GlobeNewswire Inc.Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1321:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1320:30GlobeNewswire Inc.Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer ImmunotNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1206:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1206:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1206:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1206:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/08/3020:30GlobeNewswire Inc.Sensei Biotherapeutics to Participate in Upcoming Investor ConferencesNASDAQ:SNSESensei Biotherapeutics Inc
 검색 관련기사 보기:NASDAQ:SNSE

최근 히스토리

EU
ILUES
AMUNDI LUES INAV
TG
SADE
Amundi Luxembourg
NASDAQ
ZABMFX
Adelis Fund I
BIT
F07344
Vontobel Financial Produ...
GDAX
UMAUSD
UMA Voting Token v1
TG
1JIA
Anonymous Intelligence
USOTC
GCRPF
Global Connection Public (CE)
COIN
CREDITGBP
COIN
ESCOEUR
NYSE
FTRB
Federated Hermes
BIT
F19763
Vontobel Financial Produ...
BIT
P1RI37
BNP Paribas Issuance
OKEX
STETHETH
stETH
TG
PR1Z
Amundi Luxembourg
LSE
83PG
Orig.ml.b6 32
LSE
CTAI
Catenai
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유